| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5464933 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Jun, 2013
(10 years ago) | |
| US6133418 | ROCHE | Synthetic peptide inhibitors of HIV transmission |
Nov, 2014
(9 years ago) | |
| US6475491 | ROCHE | Treatment of HIV and other viral infections using combinatorial therapy |
Jun, 2015
(8 years ago) | |
Fuzeon is owned by Roche.
Fuzeon contains Enfuvirtide.
Fuzeon has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Fuzeon are:
- US5464933
- US6133418
- US6475491
Fuzeon was authorised for market use on 13 March, 2003.
Fuzeon is available in injectable;subcutaneous dosage forms.
Fuzeon can be used as treatment of hiv.
The generics of Fuzeon are possible to be released after 07 June, 2015.
Drugs and Companies using ENFUVIRTIDE ingredient
Market Authorisation Date: 13 March, 2003
Treatment: Treatment of hiv
Dosage: INJECTABLE;SUBCUTANEOUS
More Information on Dosage
FUZEON family patents
